Fig. 1: Overall survival in patients with cT1-T2 N0 HER2-amplified breast cancer treated with neoadjuvant chemotherapy.

A cT stage was not associated with survival in patients that achieved a pCR or those with residual disease, and B single or multi-agent chemotherapy was not associated with survival in patients that achieved a pCR or those with residual disease.